ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Clovis Oncology Inc

Clovis Oncology Inc (CLVS)

0.0812
0.00
(0.00%)
Closed September 22 4:00PM
0.00
0.00
(0.00%)

Professional-Grade Tools, for Individual Investors.

Key stats and details

Current Price
0.0812
Bid
0.0792
Ask
0.0811
Volume
-
0.00 Day's Range 0.00
0.00 52 Week Range 0.00
Previous Close
0.0812
Open
-
Last Trade
Last Trade Time
Average Volume (3m)
-
Financial Volume
-
VWAP
-

CLVS Latest News

Clovis Oncology Shares Fall Premarket After Bankruptcy Filing

By Colin Kellaher Shares of Clovis Oncology Inc. slid nearly 10% in premarket trading Monday after the biopharmaceutical company said it filed for chapter 11 bankruptcy with plans to auction off...

Clovis Oncology Files for Chapter 11 Protection and Enters into Agreement to Sell FAP-2286

Receives Commitment for up to $75 Million in Debtor-in-Possession Financing Clovis Oncology, Inc. (NASDAQ:CLVS) (“Clovis” or the Company”), a biopharmaceutical company focused on acquiring...

Clovis Oncology Presents Data from TRITON3 Phase 3 Trial of Rubraca® (rucaparib) at the 29th Annual Prostate Cancer Foundation Scientific Retreat

Clovis Oncology, Inc. (NASDAQ: CLVS) today announced the presentation of data from the TRITON3 Phase 3 trial in men with metastatic castration-resistant prostate cancer with BRCA or ATM...

Clovis Oncology Highlights Updated LuMIERE Phase 1 Data of Targeted Radiotherapy Candidate FAP-2286 at the 35th Annual EANM Congress

Updated LuMIERE Phase 1 data demonstrated a manageable safety profile with some preliminary evidence of anti-tumor activity Eleven patients treated to date with 177Lu-FAP-2286 up to 7.4 GBq/dose...

TRITON3 Phase 3 Trial of Rubraca® (rucaparib) Achieves Primary Endpoint in Men with Metastatic Castration-Resistant Prostate Cancer with BRCA or ATM Mutations

TRITON3 study evaluating Rubraca monotherapy versus chemotherapy or second-line androgen deprivation therapy in patients with metastatic castration-resistant prostate cancer (mCRPC) with...

Clovis Oncology and Isotopia Announce Lutetium-177 Clinical Supply Agreement

Isotopia to supply its medical radioisotope, lutetium-177, for the clinical development of Clovis Oncology’s targeted radionuclide therapy candidate FAP-2286 Clovis Oncology, Inc. (NASDAQ: CLVS...

Clovis Oncology Submits Applications for Rubraca® Label Expansion in the US and European Union as First-line Maintenance Treatment in Women with Advanced Ovarian Cancer

Submissions based on data from the Phase 3 ATHENA trial evaluating Rubraca monotherapy versus placebo (ATHENA-MONO) presented at ASCO 2022 The ATHENA-MONO trial met its primary endpoint, showing...

Clovis Oncology’s Rubraca® (Rucaparib) as First-Line Maintenance Treatment Improves Progression-Free Survival in Women with Advanced Ovarian Cancer Across Disease Risk Subgroups

Subgroup analysis from the Phase 3 ATHENA trial evaluating Rubraca monotherapy versus placebo (ATHENA-MONO) presented in a Mini Oral session at the ESMO Congress 2022 Results reinforce potential...

Clovis Oncology Announces Second Quarter 2022 Operating Results and Provides Update on Clinical Development Programs

First presentation of initial LuMIERE Phase 1 clinical data for FAP-2286 targeted radiotherapy candidate at SNMMI demonstrated a manageable safety profile with preliminary evidence of activity...

CORRECTING and REPLACING Clovis Oncology to Announce Second Quarter 2022 Financial Results and Host Webcast Conference Call on August 8

First paragraph, second sentence of release should read: Clovis’ senior management will host a conference call and live audio webcast at 8:30am ET to discuss Clovis’ results and business outlook...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10000000CS
40000000CS
120000000CS
260000000CS
520000000CS
1560000000CS
2600000000CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
BNZIBanzai International Inc
$ 5.645
(96.01%)
61.39M
ZJYLJin Medical International Ltd
$ 3.975
(50.00%)
1.24M
ANEBAnebulo Pharmaceuticals Inc
$ 2.9001
(39.43%)
78.85k
XPONExpion360 Inc
$ 0.081
(39.18%)
1.46B
AENTAlliance Entertainment Holding Corporation
$ 2.74
(34.31%)
4.23M
GSIWGarden Stage Ltd
$ 1.34
(-82.89%)
26.44M
CRBPCorbus Pharmaceuticals Holdings Inc
$ 19.51
(-62.26%)
12.29M
LGCBLinkage Global Inc
$ 0.4183
(-57.70%)
2.16M
BFIBurgerFi International Inc
$ 0.0855
(-42.27%)
15.05M
SKYESkye Bioscience Inc
$ 3.17
(-42.26%)
5.14M
XPONExpion360 Inc
$ 0.081
(39.18%)
1.46B
NVDANVIDIA Corporation
$ 116.00
(-1.59%)
378.16M
AAPLApple Inc
$ 228.20
(-0.29%)
320.24M
INTCIntel Corporation
$ 21.84
(3.31%)
261.68M
VERBVerb Technology Company Inc
$ 0.0742
(33.45%)
178.65M

Discussion

View Full Feed
ORCA ORCA 4 minutes ago
SLOPS IS IT YOUR SHARES I KEEP BUYING??HOW MUCH HAVE YOU LEFT WITH.SELL THE REST BRO.ORCA HAS BEEN EATING UP THE FLOAT.ALMOST DAILY.KEEP THEM COMING.
VDRM
PegnVA PegnVA 6 minutes ago
Ken Burns on the ‘incredibly dangerous’ party that the GOP has ‘morphed’ into
In bestowing Ken Burns with its 2024 Liberty Medal, the National Constitution Center called him “America’s history teacher,” and he spoke to Ali Velshi about the “echoes” and “rhymes” between the current political m
nowwhat2 nowwhat2 7 minutes ago
Gave it a run.....Came within 700

https://investorshub.advfn.com/uimage/uploads/2024/9/22/evuyibtc_999_22_15d_1215_scrappy_clonk.jpg

:45 minutes later.....
https://investorshub.advfn.com/uimage/uploads/2024/9/22/tkjxibtc_999_22_15d_1pm_pump_zone.jpg
BTCUSD
excel excel 7 minutes ago
Can a red flag be thrown on PI?
If so is Atlanta coaches blind?
That was DEFINIETLY PI!
Unreal KC wasn't called for that
Slojab Slojab 7 minutes ago
And since you're not in the loop or know the people in the loop, your post is pure nonsense.

And the election has nothing to do with anything.
USEI
BDEZ BDEZ 8 minutes ago
Well you still play basketball as well so you must be in good shape...great that you still work out.
StayHumble StayHumble 8 minutes ago
🟩.🟩🟩🟩🟩🟩 Rocketship in the making $HCWC $HCMC $Huzzah imo.
HCMC HCWC HUZZAH
Tadaaa Tadaaa 8 minutes ago
The Truth is coming out, sad but true, WOW

https://truthsocial.com/@ThePatriotVoice/113183051231013794
ORCA ORCA 8 minutes ago
LMAO.YOU STUPID F,THIS WEEK ALONE I BOUGHT 5,5 MILLION.WHO ARE YOU TALKING TOO??OR MAYBE IT GOES DOWN TO TRIPLE ZEROS.WHAT DO YOU THINK??SHALLL IT BECOME AN EVENT??TRIPLE ZEROS??YEA WHY NOT.OR ZERO BID.EVEN BETTER??
09/16/2024 Buy
Trade Details
ILUS
ILUSTRATO PICTURES
ILUS
StayHumble StayHumble 10 minutes ago
🟩.🟩🟩🟩🟩🟩 Rocketship in the making $HCWC $HCMC $Huzzah
HCWC
Gary Ray Gary Ray 11 minutes ago
Doesn’t change a thing. Can easily open at $10.50 at the bell - which it might lol
Unpredictable cowboy play.
CONY
StayHumble StayHumble 11 minutes ago
@healthiercmc $HCWC🟩🟩🟩"Enforce.Monetize.License.Protect." $HCMC also related


https://static1.squarespace.com/static/58a1d7b8893fc0b6d3e47931/t/63599cf2e6708456f8187f4c/1666817273168/HCMC_LDMicroOct2022.pdf
HCMC HCWC
The Night Stalker The Night Stalker 13 minutes ago
0006 break coming
ICTY
asp42001 asp42001 14 minutes ago
Spanish FiCentive/Akimbo Advantage AD Promo/Demos?

S.A. & Austin, TX offices must advertise USIO & Akimbo Cards in Spanish!

Management's Billserv (BLLS) Op circa 1998, catered to Latinos & others.

DEAL!
USIO
Gary Ray Gary Ray 14 minutes ago
Doooood
Love pinkies, so many good ones out there now that the sky is falling.

You not holding at all?
ENMI
wadegarret wadegarret 14 minutes ago
north40000- VIK vs NCLH

North, which do you like better, VIK of NCLH ? The PEG ratio is very close for both, at slightly less than .5, but the balance sheet is better with NCLH. VIK actually has a negative net assets of around $1.1B, which is 10% more liabilities than assets. NCLH
NCLH
StayHumble StayHumble 14 minutes ago
@healthiercmc $HCWC $HCMC🟩🟩🟩"Enforce.Monetize.License.Protect."


https://static1.squarespace.com/static/58a1d7b8893fc0b6d3e47931/t/63599cf2e6708456f8187f4c/1666817273168/HCMC_LDMicroOct2022.pdf
HCMC HCWC
CorsairNavigator20 CorsairNavigator20 15 minutes ago
Sorry to hear about the autimmune prognosis. I wish you the best.
MRKR
nickeli54 nickeli54 15 minutes ago
Yep this one has a lot of promise here
AFFU
Longstrongsilver Longstrongsilver 15 minutes ago
I think he’s just a guy on Twitter with lots of followers who follows and tags BLEG. . So when he made a post Dave commented/replied or reteeeted or whatever “oh if you’re happy now blah blah blah contracts updates 3-5 weeks…. “
BLEG
CorsairNavigator20 CorsairNavigator20 16 minutes ago
It sounds as if it is fully enrolled. Now comes the waiting period to see if safety is met as well as any other requirements for the completion of phase 1.
Time is needed to see objective response rate and duration as well as summarize the data for the FDA
MRKR
Zardiw Zardiw 16 minutes ago
$CBMJ - https://Patriot.TV - Revenues up 500%:

They have https://Patriot.TV - A conservative news media site.

1. Increases in quarterly revenue of $486K for the quarter ending 6-30-24
growing 532% over the same period in 2023.

2. For t
CBMJ
nickeli54 nickeli54 16 minutes ago
💪
AAGC
Zardiw Zardiw 17 minutes ago
$CBMJ - https://Patriot.TV - Revenues up 500%:

They have https://Patriot.TV - A conservative news media site.

1. Increases in quarterly revenue of $486K for the quarter ending 6-30-24
growing 532% over the same period in 2023.

2. For t
CBMJ
Zardiw Zardiw 17 minutes ago
$CBMJ - https://Patriot.TV - Revenues up 500%:

They have https://Patriot.TV - A conservative news media site.

1. Increases in quarterly revenue of $486K for the quarter ending 6-30-24
growing 532% over the same period in 2023.

2. For t
CBMJ